**Appendix 1. Full inclusion and exclusion criteria**

**Full inclusion criteria**

The inclusion criteria were as follows:

• Man aged 18 to 50 years at the inclusion visit,

• HIV-1 infection (confirmation by a complete western blot or by pre-inclusion plasma RNA determination),

• Ongoing cART of more than six months’ duration with an undetectable plasma viral load (last sampling less than four months before the pre-study visit),

• Absence of co-infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) (last negative serological test less than six months before the pre-study visit),

• Free, informed, written and signed consent given by the patient and the investigator at the pre-inclusion visit and before any examination required by the test (Article L1122-1-1 of the Public Health Code),

• Affected patient covered by a social security scheme of a member country of the European Union (Article L1121-11 of the French Public Health Code).

**Full exclusion criteria**

The exclusion criteria were as follows:

• HIV-2 infection,

• All stages of cirrhosis,

• Severe kidney failure (creatinine clearance of 30 mL/min),

• Opportunistic infection in the past or on treatment,

• Cancer undergoing treatment,

• Testosterone or another anabolic agent, anti-androgenic drugs, GnRH analogs (gonadotrophin-releasing hormone), estrogens, glucocorticoids, growth hormones or growth factor IGF-1 (insulin-like growth factor-1) taken within the last three months,

• Known pituitary, testicular or adrenal disease, whether or not treated,

• Present or past history of psychotic disorders and/or high suicide risk,

• Refusal to participate,

• Ward of court,

• Patient participating in another study including an exclusion period not yet elapsed at the pre-inclusion visit.